NCT05820191View on ClinicalTrials.gov

B-amyloid as a Marker for GBM Bioimaging

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Glioblastoma
Interventions
DRUG

Amyvid, Intravenous Solution

Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.

Trial Locations (2)

00956

Central University of the Caribbean (UCC), Bayamón

0921

University of Puerto Rico, Medical Science Campus, San Juan

All Listed Sponsors
collaborator

University of Puerto Rico

OTHER

lead

Universidad Central del Caribe

OTHER